Stocks on broker’s radar: Trent’s stock is in focus today. The company expects 25% CAGR in sales in 5 to 10 years. The company says that growth will increase with store expansion, new category and cost control. There is a cautious attitude about the brand of Star Format. Supply chain take investment is possible to benefit in fashion. On this, brokerage has given outperform rating. Apart from this, stocks like Biocon, Titan have also come on the brokerage radar today. The brokerage firm on Titan has given a neutral call. Know what rating the brokerage has given on other stocks.
The Macquelite has given an outperform rating on Trent. Its target has been fixed at Rs 7200. He says that the company’s target of 25% sales growth annually in 5–10 years. The company will have focus on new stores, new categories and cost control. The company has a cautious attitude towards the star format. Supply chain take investment can help in competition in fashion space.
Giving opinion on Titan, the city said that this time there is more competition from last year, but the company’s poor era is over. The current level of margin appears to be stable. In 2-3 years, Tanishq has rationalized the making charge. The company has insisted on increasing the scale for growth. According to the company, the scale and strategic value will be done only to increase M&A. Brokerage has given a neutral rating on stock. Its target has been fixed at Rs 3800.
HSBC has given the opinion of shopping on Biocon. Its target has been fixed at Rs 390. He says that a QIP of Rs 4,500 crore has been launched to repay the loan. Successful QIP will increase leverage. The expansion of new biosimilars is necessary for turnaround. The launch of Insulin ASPART is important in FDA approval and US.
(Disclaimer: The ideas and investment advice on Moneycontrol.com have their own personal views and opinions. Moneycontrol advises users to consult certified experts before making any investment decisions.)